They have isolated the molecular ‘weapons’ of the bacterium and are now assessing ways to make the bacterium impotent.
Scientists in the University’s Department of Biochemistry are focusing on two proteins in the TB bacterium which, it is thought, allows it to thrive in white blood cells.
They are particularly examining a ‘long arm’ in a molecule of the bacterium which is thought to be used to bind onto white blood cells. The scientists are also seeking to identify which part of the white blood cell is being targeted.
Dr. Mark Carr, from the Department of Biochemistry said: “If you were to ask most people about TB, they would have most likely told you it was no longer a threat, merely a memory of a Britain with an undeveloped healthcare system.
“But TB is on the rise around the world with the number of new reported cases nearly doubling in the past 25 years. The World Health Organisation reported 8,500 instances in the UK in 2005.
“At the University of Leicester, our aim is to take the molecular ‘weapons’ of TB and isolate them, to understand their function and hopefully find a way to minimise their effects.
“One of the most important of these molecular weapons is known as the ESAT-6/CFP-10 complex. These are two proteins that bind together to become a functional unit, and it is thought that they may be needed to allow the bacteria to thrive inside white blood cells, as happens during the initial infection. Removal of the genes for this complex from the TB genome renders the bacteria unable to cause disease, exposing how important this particular weapon is to the bacteria.
“Similarly, studies of the structure of the protein complex have shown that removal of a ‘long arm’ from the molecule prevents the complex’s ability to bind to the outer surface of human white blood cells. This data has provided us with a potential insight into the important components of this complex.”
Dr. Carr added: “Current work is attempting to identify the exact components of the human white blood cells that this complex is targeting. Once found, this should give us a greater knowledge of the action of these molecular weapons of TB and give us the edge in the war against an ancient, reawakened foe.”
Source: University of Leicester
Related stories:
Statins may prevent miscarriages
Hospital for Special Surgery researchers have found that statins may be able to prevent miscarriages in women who are suffering from pregnancy complications caused by antiphospholipid syndrome (APS), according to a study in mice. In this autoimmune syndrome, the body produces antibodies directed at phospholipids, the main components of cell membranes. This news comes from a study published in the October issue of the
Journal of Clinical Investigation that is currently online in advance of print.
Scientists discover crucial control in long-lasting immunity
National Institutes of Health (NIH) scientists have identified a protein that plays matchmaker between two key types of white blood cells, T and B cells, enabling them to interact in a way that is crucial to establishing long-lasting immunity after an infection. Their finding may also explain why some individuals who have a genetic defect that prevents them from making this protein—called SAP—suffer from lethal infections with a common virus that otherwise is rarely fatal (Epstein-Barr virus), while others with this genetic defect have problems with B-cell lymphomas.
Time of day influences yield for pharmacologically stimulated stem cell mobilization
A new study uncovers a previously unrecognized, species-specific impact of circadian rhythms on the production of mobilized stem cells. The research, published by Cell Press in the October 9th issue of the journal
Cell Stem Cell, suggests that when it comes to collecting human stem cells for clinical transplantation, picking the right time of day to harvest cells may result in a greater yield.
Strong association found between prevalence of low white blood count and women of African descent
Researchers from Columbia University Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, have found a strong association between women of African descent from the U.S. and Caribbean, who are otherwise healthy, and the prevalence of neutropenia, or low white blood count. Neutropenia, which is associated with race and ethnicity, has essentially been unexplained and, although thought to be benign, may affect therapy for cancer or other illnesses. Among women of African descent who develop a malignancy, this association may contribute to racial disparities in treatment and outcomes. The study findings are reported online in Blackwell Publishing Ltd.
British Journal of Hematology (August 2008).
New leukemia signal could point way to better treatment
Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.
Pores open the door to death
(PhysOrg.com) -- Our body is almost constantly being threatened by pathogens and cancerous cells that appear out of the blue. But the body puts up a fight: specialized cells in the immune system smuggle small molecules (granzymes) into cancer cells and those body cells that have fallen prey to viruses. The molecules then trigger off the diseased cells' built-in suicide program. There are two possible ways in which the granzymes gain entry into the cells under attack.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
New synthetic form of protein holds promise to stop cancer spread
Researchers at the Medical College of Wisconsin in Milwaukee have a pending patent on a new synthetic form of a protein involved in certain types of cancers and immune system diseases.
